Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takeda Pharmaceuticals U S A Inc. has 2 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These cases are handled by 2 distinct examiners, which distributes the prosecution workload across different individuals. The matters are also located in 2 distinct art units, indicating that the company's pharmaceutical filings are being reviewed under different technical classifications at the USPTO.
SULLIVAN, STEPHANIE LAUREN is the busiest examiner for the company, with 1 pending office action currently under review. With 2 pending office actions in total, the workload is shared between the 2 distinct examiners. The involvement of 2 distinct art units suggests that the company is pursuing multiple technical paths within the biotechnology field. Practitioners must adapt to the specific preferences of two different examiners rather than focusing on a single point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566561 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | SULLIVAN, STEPHANIE LAUREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998085 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | WHITEMAN, BRIAN A | 58d overdue |
| 18566561 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | SULLIVAN, STEPHANIE LAUREN | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566561 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | SULLIVAN, STEPHANIE LAUREN | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 17998085 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | WHITEMAN, BRIAN A | 1636 | §112 | Final Rejection | 58d overdue | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakeda Pharmaceuticals U S A Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Stephanie Lauren Sullivan has the most, with 1 of Takeda Pharmaceuticals U S A Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
